



Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort

Jolanta Majcher-Peszynska, Marko Sass, Sora Schipper, Viktor Czaika, Andreas Gussmann, Ralf Lobmann, Ralf G. Mundkowski, Christoph Luebbert, Peter Kujath, Bernhard R. Ruf, et al.

► To cite this version:

Jolanta Majcher-Peszynska, Marko Sass, Sora Schipper, Viktor Czaika, Andreas Gussmann, et al.. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. *European Journal of Clinical Pharmacology*, 2010, 67 (2), pp.135-142. <10.1007/s00228-010-0903-5>. <hal-00626284>

HAL Id: hal-00626284

<https://hal.science/hal-00626284v1>

Submitted on 25 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

Title:

Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort

Authors:

Jolanta Majcher-Peszynska¹, Marko Sass², Sora Schipper², Viktor Czaika³, Andreas Gussmann³, Ralf Lobmann⁴, Ralf G. Mundkowski¹, Christoph Luebbert⁵, Peter Kujath⁶, Bernhard R. Ruf⁷, Horst Koch⁸, Wolfgang Schareck², Ernst Klar², Bernd Drewelow¹ for the Moxifloxacin-DFI Study Group

Institute of Clinical Pharmacology, Centre of Pharmacology and Toxicology
University of Rostock
Schillingallee 70, 18057 Rostock, Germany

¹Institut für Klinische Pharmakologie des Zentrums für Pharmakologie und Toxikologie der Universität Rostock, Schillingallee 70, 18057 Rostock, Germany

²Chirurgische Klinik und Poliklinik, Abteilung für Allgemeine, Thorax-, Gefäß- und Transplantationschirurgie, Universität Rostock, Schillingallee 35, 18057 Rostock, Germany

³HELIOS Klinikum Bad Saarow, Klinik für Gefäßchirurgie, Pieskower Str. 33, 15526 Bad Saarow, Germany

⁴Department of Endocrinology, Diabetology and Geriatrics, General Hospital Stuttgart, Tunzhofer Straße 14-16, 70191 Stuttgart, Germany

⁵Klinikum der Martin-Luther-Universität Halle-Wittenberg, Klinik und Poliklinik für Innere Medizin I, Ernst-Grube-Strasse 40, 06097 Halle (Saale), Germany

⁶ Klinik für Chirurgie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

27 ⁷ Innere Medizin 2, Städtisches Klinikum „St. Georg“ Leipzig, Delitzscher Straße 141, 04129
28 Leipzig, Germany

29 ⁸Oder-Spree Krankenhaus GmbH Beeskow, Schützenstraße 28, 15848 Beeskow

30

31 Corresponding author:

32 Dr. Jolanta Majcher-Peszynska

33 Institute of Clinical Pharmacology

34 University of Rostock

35 Schillingallee 70

36 D – 18057 Rostock

37 Germany

38 Tel: +49-381-494-5969 ; Fax: +49-381-494-5839

39 E-Mail: jolanta.majcher-peszynska@uni-rostock.de

40

41 Running title: Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot
42 tissue

43

44 Keywords: pharmacokinetics in diabetes, tissue penetration, moxifloxacin, diabetic foot, skin
45 and skin structure infection

46

Abstract

Objectives:

Physiological changes occurring in patients with diabetes may affect pharmacokinetics and penetration of antimicrobial agents into peripheral tissue. We examined the pharmacokinetics and the penetration of moxifloxacin into perinecrotic tissue of diabetic foot lesions in patients with diabetic foot infections (DFI).

Patients and methods:

Adult patients suffering from type 2 diabetes mellitus and hospitalized for DFI (Texas classification of at least B2) were treated with 400 mg moxifloxacin intravenously (IV) or orally (PO) once daily. Pharmacokinetics of moxifloxacin and its concentration 3 hours after administration in samples of perinecrotic tissue resected from infected diabetic foot wounds were determined at steady state (day 4 to 8).

Results:

A total of 53 patients with diabetes mellitus type 2 (mean age of 69.4 ± 10.8 years) were included in the study, of whom 28 received PO and 25 IV moxifloxacin therapy for a median of 8 days. In the PO and IV subgroups mean C_{\max} in plasma was 2.69 mg/L and 4.77 mg/L at a median of 2.0 h (T_{\max} range of 1.0-8.0 h) and 1h after administration, respectively. An AUC_{0-24h} with a mean of 29.36 mg/L (PO) and 27.09 mg·h/L (IV) was achieved. Mean moxifloxacin concentrations in perinecrotic tissue of infected diabetic foot wounds following PO or IV administration were 1.79 ± 0.82 µg/g and 2.20 ± 1.54 µg/g, thus exceeding the MIC_{90} for *Staphylococcus aureus* (0.25 mg/L) 7-fold and 8.5-fold and the MIC_{90} for *E. coli* (0.06 mg/L) 29-fold and 36-fold, respectively. The mean tissue-to-plasma ratios of moxifloxacin concentration 3 h after administration were 1.01 ± 0.57 (PO) and 1.09 ± 0.69 (IV), respectively. Significant differences between the routes of administration were observed

for T_{\max} and C_{\max} , ($p < 0.01$), but not for other clinically relevant parameters (AUC_{0-24} ,
moxifloxacin DFI tissue concentration).

Conclusions:

The plasma concentration time curve of moxifloxacin in diabetic patients is similar to that of
healthy volunteers. We also observed a good penetration of moxifloxacin into inflamed DFI
tissue, which taken together with the possibility of sequential therapy IV / PO designate
moxifloxacin 400 mg once daily as a therapeutic option in the treatment of DFI caused by
susceptible organisms.

85

86 Foot complications are among the most common sequelae of diabetes mellitus and the most
87 important cause for hospitalization of diabetic patients [1]. Up to one in five patients with
88 diabetes will develop a foot ulcer during the course of disease and about 60% of these will be
89 clinically infected [2]. Diabetic foot infections (DFI) may lead to amputation of the involved
90 limb and are actually responsible for 85% of diabetes-related lower-extremity amputations.

91

92 Though DFI are a complex problem and require multidisciplinary management [1], a prompt
93 and appropriate antibacterial therapy plays a key role and may contribute to the prevention of
94 amputations [1-3]. Complicated skin and skin structure infections (cSSSIs), including diabetic
95 foot infections, are often polymicrobial, requiring broad-spectrum combination therapy.

96

97 For an effective therapy, the antimicrobial agent has to reach an adequate concentration in the
98 involved peripheral tissue [1, 4, 5]. However, this goal may not be reached in this patient
99 population and for this site of infection. Physiological changes resulting from the underlying
100 diabetic conditions such as acidotic metabolic status, reduced blood flow and altered
101 microenvironment may interfere with the distribution of antibiotics in plasma and tissue.
102 Local inflammatory processes and fibrotic boundaries in the diabetic foot can additionally
103 impair tissue penetration at the site of infection [4, 5].

104

105 As the fluoroquinolone moxifloxacin is a broad-spectrum antibiotic with high *in vitro* activity
106 against gram-positive and gram-negative aerobes and anaerobes including the pathogens
107 commonly found in DFI [6], it may be potentially useful for initial empirical therapy.
108 Moxifloxacin's once daily dose regimen with the possibility of sequential IV/PO therapy
109 offers an advantage to the other current antibiotic regimens used in the treatment of DFI.
110 Sequential therapy of moxifloxacin is approved for the treatment of adults with complicated

skin and skin-structure infections (cSSSIs), including DFI, though its efficacy in osteomyelitis has not been investigated yet.

An earlier pharmacokinetic study in five diabetic patients with peripheral arterial occlusive disease and soft tissue infections has shown that after a single 400-mg dose of moxifloxacin, effective concentrations are attained in the interstitia of healthy and inflamed subcutaneous adipose tissue of the thigh and in plasma [7].

The present study was set up to investigate the penetration of moxifloxacin into perinecrotic tissue of infected diabetic foot lesions in a large patient cohort and to evaluate its pharmacokinetic profile in a pharmacological risk population of diabetic patients.

Patients and methods

The study population of this prospective, open, multicenter study consisted of male and female patients with type 2 diabetes mellitus hospitalized for DFI graded with a Wagner score of 2 or 3 (equivalent to Texas Diabetic Wound classification of at least B2) and requiring antibacterial therapy.

The following main exclusion criteria were applied: Patients below 18 years of age, with hypersensitivity against quinolones, severe liver dysfunction (Child Pugh class C), heart failure with reduced left ventricular ejection fraction (NYHA III-IV), arrhythmia requiring medical treatment, signs of severe arterial occlusive disease of the lower limbs (Fontaine stages III-IV) or chronic renal insufficiency requiring dialysis.

Written informed consent was obtained from all patients, and the study protocol was approved by the responsible Ethics Committees.

137

138 All patients were monitored for adverse events.

139

140 **Sampling and analytical method**

141 Between days 4 and 8 after start of moxifloxacin treatment the plasma levels were determined
142 (steady-state). The venous blood samples were taken immediately before (baseline) and at 1,
143 2, 3, 4, 6, 8, 10, 12, and 24 hours after start of 1h-infusion of 400 mg moxifloxacin (following
144 once daily IV administration) or after once daily administration of moxifloxacin 400 mg PO.
145 Blood samples (2.7 mL) were collected in EDTA containing tubes and immediately
146 centrifuged at 4°C and 2,000 x g for 5 min. Then, plasma was separated, snap frozen at -20°C
147 and stored at -80°C until analysis.

148 The concentration of moxifloxacin was determined by means of high performance liquid
149 chromatography (HPLC).

150 Plasma aliquots of 100 µl were spiked with 10 of aqueous ofloxacin (final concentration 200
151 µg/L) as internal standard and, in case of the calibrators, appropriate concentrations (100 –
152 1600 µg/L) of moxifloxacin. Then, 20 µl of 50% TFA was added, the mixture was vortexed
153 and centrifuged at 6000xg for 4 min. Of the supernatant 80 µl was added to 21 µl of 5.0 M
154 NH₄OAc, and 20 µl of the mixture subjected to HPLC/fluorescence analysis. The
155 chromatographic system consisted of a guarded YMC Pro C₁₈ 120/5 column, 150 x 2 mm i.d.
156 maintained at 20°C, and a gradient mobile phase comprising of components A (MeOH/1.0 M
157 NH₄OAc/H₂O 10:5:85 v/v/v) and B (40:5:55) pumped at a rate of 250 µl/min, with 22%
158 initial B changed to stages of 25%, and 32% after 1 and 2 min, respectively. Detection was
159 performed by the emission at 504 nm at an excitation wavelength of 296 nm. The retention
160 times were 4.5 and 12.5 min for ofloxacin and moxifloxacin, respectively. The assay was
161 validated intra- and inter-daily according to standard procedures with precisions (CV) and
162 accuracies (RE) better than ± 15%; the lower limit of quantification (LLOQ) was calculated

50 µg/L allowing for a deviation of CV and RE < ±20%. Recoveries ranged between 85 and 90% based on spiking solution.

Specimens of at least 100 mg of perinecrotic wound tissue of infected diabetic foot lesions were collected during second wound debridement between days 4 and 8 of antimicrobial treatment and approximately three hours after administration of moxifloxacin. The tissue samples were gently blotted with absorbent paper to remove excrescent blood, snap frozen in liquid nitrogen and stored at -80°C until analysis. Moxifloxacin concentration was determined in the homogenized tissue samples by high-performance liquid chromatography with fluorescence detection as described in detail previously [8].

Pharmacokinetic calculations and statistics

Pharmacokinetic parameters were calculated by noncompartmental analysis with Kinetika 4.4 software (Thermo Scientific, Dreieich, Germany). The maximum observed plasma concentrations (C_{\max}) and time to reach C_{\max} (T_{\max}) after moxifloxacin administration were determined from the concentration-time curves. The area under the plasma concentration-time curve from time 0 until the last quantifiable plasma concentration (AUC_{0-24h}) was calculated by using the linear trapezoidal rule. DFI tissue/plasma ratio was estimated using corresponding concentration of moxifloxacin in plasma (three hours after administration of moxifloxacin).

All data were analyzed descriptively. Calculations were performed using the SPSS software release 15.0 (SPSS GmbH, Munich, Germany). For all variables, arithmetic mean values, standard deviations, ranges and the 95% confidence intervals (CI 95%) were calculated, with the exception of T_{\max} , for which only median and minimum-maximum ranges are given.

Relationships were evaluated using nonparametric Spearman-Rho correlation coefficient.

A two-sided *P* value of <0.05 was considered the level of significance.

Results

Fifty three patients with DFI were enrolled into the study at nine centres in Germany. At study entry, the patients had a mean age of 69.4 ± 10.8 years, a mean body weight of 82.9 ± 17.9 kg and a mean body mass index (BMI) of 28.2 ± 4.5 kg/m². Mean C-reactive protein (CRP) was 76.9 ± 80.4 mg/L, mean leukocyte count was 11.0 ± 3.5 Gpt/L and average serum creatinine was 121.6 ± 97.5 µmol/L.

Moxifloxacin 400 mg once daily was administered PO to 28 patients and IV to 25 patients for a median of 8 days (range: 4-19). Patients' assignment to IV or PO administration of moxifloxacin followed clinical considerations. As shown in Table 1, both cohorts were similar in their demographic characteristics and laboratory variables at baseline.

In one patient of the IV cohort the amount of tissue collected was too small to measure tissue concentration.

Study drug treatment was well tolerated. No serious adverse events were observed and none of the patients had to be excluded due to adverse events.

The most frequent treatment-emergent adverse event was diarrhea, occurring in 6 patients (10.5%).

The reduction of body temperature by 2.8 degrees C ($p < 0.01$) and C-reactive protein by 1.4 mg/L ($p > 0.05$) at the end of the therapy can indicate an antiinfective effect of moxifloxacin.

Steady-state concentrations of moxifloxacin in plasma (median for both cohorts: day 6) are shown in Figures 1 and 2 and summed-up in Table 2. Significant differences between the routes of administration (IV vs PO) were only observed for C_{\max} and T_{\max} in plasma ($p < 0.01$), but not for other relevant pharmacokinetic parameters.

215

216 Mean moxifloxacin concentrations at steady state (median for both cohorts: day 6) in
217 perinecrotic tissue of infected diabetic foot wounds are shown in Table 3. The mean tissue
218 concentrations for PO or IV administration did not differ significantly ($p>0.05$). The
219 concentrations of moxifloxacin achieved in DFI tissue correlated more strongly with the
220 AUC_{0-24} ($r=0.659$; $p<0.01$) than with the corresponding (3h) plasma values ($r=0.492$, $p<0.01$).

221

222 Mean tissue concentration of moxifloxacin exceeded the *in vitro* MIC_{90} for *Staphylococcus*
223 *aureus* (0.25 mg/L) [6, 9, 10] 7-fold and 8-fold and the MIC_{90} for *E. coli* (0.06 mg/L) [6] 29-
224 fold and 36-fold, respectively.

225

226 Based on these *in vitro* MIC_{90} for *Staphylococcus aureus* and *E. coli* fluoroquinolone-relevant
227 PK/PD-parameters of moxifloxacin were calculated (see Table 4). Taking into account the
228 predictive PK/PD parameters for moxifloxacin a therapeutic success can be expected in both
229 administration routes.

230

231 Discussion

232 For diabetic foot infection as well as for necrotizing fasciitis the lowest clinical cure rates of
233 skin and skin-structure infections are reported [11]. Of the fluoroquinolones licensed,
234 moxifloxacin is the only one demonstrating activity against anaerobe pathogens. This activity,
235 along with its rapid bactericidal effect and its high *in vitro* activity against gram-positive and
236 gram-negative bacteria, make moxifloxacin especially attractive as a potential single-drug
237 regimen for initial antibacterial therapy of mostly polymicrobial DFI, except for methicillin-
238 resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa* [9].

239 Similar to other fluoroquinolones, moxifloxacin penetrates well into peripheral compartments
240 and achieves high concentrations in many tissues, including skin and soft tissue [2, 15].

However, the present study is the first to investigate moxifloxacin penetration into perinecrotic tissue (i.e. the transition zone between healthy and necrotic tissue) of patients with an inflamed DFI.

To the best of our knowledge, it is also the largest pharmacokinetic study of antibiotic penetration into tissue of infected diabetic feet.

We observed significant differences between the routes of administration (IV vs PO) only for C_{\max} and T_{\max} , but not for AUC_{0-24h} . In general, the plasma pharmacokinetics of moxifloxacin including total exposition were similar to those in healthy volunteers and patients after multiple doses, with the exception of T_{\max} which was higher and more variable in our patient population [13]. Physiological changes occurring in patients with diabetes, e.g. diabetic gastroenteropathy with delayed gastric emptying and intestinal transit times or diabetic nephropathy can be a reason for the extended time to reach C_{\max} (T_{\max}) in our study [4, 5, 12]. High variability of pharmacokinetic parameters in patients with diabetes was also seen in further studies with other antibiotics, e.g. linezolid or daptomycin [5, 12].

It is recognized that effective concentrations of antibiotics must be achieved in tissues for successful clinical outcomes of antimicrobial therapy. The fast decline of the plasma concentrations after the end of infusion in our study indicates a rapid distribution of moxifloxacin, V_{ss} was very high in agreement with previous reports [7, 13]. Plasma protein binding, which as long been considered one of the important physicochemical characteristics of antibacterials has been shown to substantially affect tissue penetration and the volume of distribution of antimicrobial agents. Independent of the drug concentration, only 40–42% of moxifloxacin is bound to plasma proteins, mainly to serum albumin, leaving most of the drug in an unbound, active form [15]. Many factors other than plasma protein binding play a role in extravascular transfer and tissue distribution of drugs, such as lipid solubility, size of the

molecule and its degree of ionization. A low molecular weight (437), a zwitterionic nature and a low protein binding of moxifloxacin may be a reasons for its high tissue penetration. Host-related factors such as site of infection, presence of biological barriers, local pH and bacterial inoculum size may contribute to the inhibition of antibacterial diffusion and antibacterial activities [20]. In diabetic patients conditions such as acidotic metabolic status, reduced blood flow, altered microenvironment, local inflammatory processes and fibrotic boundaries can impair penetration of antimicrobial agents in the diabetic foot tissue [4, 5].

The mean inflamed DFI tissue to plasma concentration ratio in the present study was about 100% for both PO and IV administration. The measured concentrations were lower than those in other tissues, e.g. gastrointestinal or bronchial tissue [17, 18]. This difference might be explained by a lower perfusion in DFI tissue due to impaired macro- and/or microcirculation. Another reason could be the perinecrotic nature of the resected DFI tissue. Our results confirm previous data of an in vivo microdialysis study, in which an enrichment of moxifloxacin was found in well-perfused inflamed subcutaneous tissue compared to plasma [7]. In the same study diabetes mellitus patients with peripheral arterial occlusive disease were investigated. In this patient population, the tissue to plasma ratio was 0.5 underlining the implication of circulatory disturbances.

The data of the presented study can be analyzed using various pharmacodynamic and pharmacokinetic indices, which are applied to predict clinical outcome. Pharmacokinetic (PK)/pharmacodynamic (PD) considerations are important in optimizing both antibacterial activity and the development of resistance. Optimal PK/PD indices have been described in plasma for the antimicrobial efficacy of moxifloxacin (area under the concentration-time curve over 24 h at steady state divided by the MIC (AUC) >30 [h] as the PK/PD surrogate parameter, which is predictive for a positive clinical outcome) [14]. Assuming that the

PK/PD concept is valid for DFI, the indices calculated from these study data (mean AUC of 108.4-117.4 for *Staphylococcus aureus*) account for a high efficacy.

The present study might be limited by the fact that tissue concentration was measured at one single time point (3 h after administration), what certainly must not correspond to the T_{max} , so that higher concentrations of moxifloxacin in DFI tissue during a whole dosage interval are possible.


Another limitation might be that moxifloxacin concentration was determined in homogenized tissue samples which do not allow to separate between different compartments. In biopsy samples, the drug is extracted from homogenized tissue comprising cells, extracellular matrix and extracellular space fluid. For drugs that accumulate intracellularly (e.g. fluoroquinolones), the biopsy method can overestimate effective drug concentrations in the interstitial space fluid, which represents the anatomical site for most bacterial infections. Moxifloxacin penetrates phagocytic and nonphagocytic cells (polymorphonuclear leukocytes and epithelial cells), reaching intracellular concentrations several times higher than extracellular ones. The intracellular penetration of moxifloxacin seem to be rapid, reversible, and affected by environmental temperature, pH and metabolic inhibitors. Moxifloxacin seem partially to require an active process, which allow easier penetration of cell membranes. Tissue inactivation of antibacterials can occur at infection sites by binding to interstitial fluid proteins, soluble intracellular proteins or subcellular structures (nucleic acids, leucocytic chromatin, cell membranes and mucopolysaccharides) [21]. The microdialysis technique, as opposed to the biopsy, determines exclusively free concentrations of antibiotics in the interstitial space fluid. This technique is based on the principle of diffusion of solutes through a semipermeable membrane due to a concentration gradient between the interstitial microenvironment and the fluids within a microdialysis probe inserted into a tissue of interest.

Even if the method of microdialysis has many advantages over a biopsy, the authors consider the biopsy with a lower invasivity and a higher feasibility (equipments, resources) as more suitable to conduct a study at such a large population of patients. The tissue concentrations of moxifloxacin found in the present study support the good clinical results observed with this fluoroquinolone in DFI [2, 11, 16]. In a recent prospective, randomized, multinational clinical study treatment with sequential IV/PO moxifloxacin, 400 mg once daily was clinically comparable to that with IV amoxicillin/clavulanate 1,000 mg/ 200 mg three times daily followed by PO amoxicillin/clavulanate 500 mg/125 mg three times daily for 7-21 days in hospitalized patients with cSSSIs [11]. *Staphylococcus aureus* and *Escherichia coli* were the most frequently isolated pathogens. In a subgroup analysis of 127 patients with DFI from a prospective double-blind study in patients with complicated skin and skin-structure infections, moxifloxacin was shown to be at least as effective as piperacillin-tazobactam (IV) followed by amoxicillin-clavulanate (PO) in the treatment of moderate-to-severe DFI [2]. In the RELIEF study (a prospective, randomised, double-dummy, double-blind, multinational, multicentre study), IV/PO moxifloxacin was clinically non-inferior to IV piperacillin/tazobactam 4.0/0.5 g thrice daily followed by PO amoxicillin-clavulanic acid in the treatment of patients with complicated skin and skin structure infections including those with DFI [16, 19].

Conclusions

Adequate drug concentrations were achieved in plasma of diabetic patients and in perinecrotic areas of diabetic foot wounds following IV as well as PO administration of moxifloxacin 400 mg once daily in a large cohort of diabetic patients with foot infections. This finding, taken together with the good clinical data, support a role for moxifloxacin in the initial therapy of patients with DFI.

345




346

347

Figure 1. Mean steady-state concentrations of moxifloxacin (400 mg once daily PO) in plasma of diabetic patients (n=28).

348



349

350

Figure 2. Mean steady-state concentrations of moxifloxacin (400 mg once daily IV) in plasma of diabetic patients (n=25).

351

352

353

354 **Table 1.** Patients' demographic and clinical characteristics at baseline (n=53)

Parameter	PO cohort (n = 28)	IV cohort (n = 25)
Age (years)	68.8 ± 9.8 (47-86)	70.0 ± 11.9 (42-93)
Male/Female ratio	2.1	1.8
Male n (%)	19 (67.9)	16 (64)
Female n (%)	9 (32.1)	9 (36)
Body weight (kg)	87.2 ± 17.4 (52-123)	77.9 ± 17.5 (51-110)
Body mass index (kg/m ²)	29.5 ± 4.3 (22.9-40.6)	26.7 ± 4.3 (16.0-37.2)
CRP (mg/L)	66.9 ± 76.3 (0.2-329.0)	91.9 ± 89.3 (1.7-345.4)
Leukocyte count (Gpt/L)	10.2 ± 2.1 (7.0-14.5)	11.4 ± 4.4 (4.9-26.4)
Serum creatinine (μmol/L)	118.7 ± 47.7 (52-245)	129.1 ± 139.4 (51.0-755.0)

355 values as mean ± SD (range)

356 **Table 2.**

357 Steady-state pharmacokinetic parameters of moxifloxacin in plasma following PO or IV
 358 administration of 400 mg once daily to diabetic patients with DFI (n=53)

Route of administration	PK parameter	Mean (SD)	95% CI	Range
PO (n=28)	C _{max,ss} (mg/L)	2.69 (0.94)	2.4; 3.0	0.9 – 4.8
	T _{max,ss} (h)	2.0 ^a	–	1.0 – 8.0
	AUC _{0-24h,ss} (mg·h/L)	27.09 (10.86)	23.1; 31.1	10.4-52.7
	V _{ss} (L/kg)	2.34 (0.96)	2.0; 2.7	1.2 – 4.7
	Cl _{tot,ss} (L/h)	14.13 (7.5)	11.4; 16.9	4.0 – 35.4
IV (n=25)	C _{max,ss} (mg/L)	4.77* (1.87)	4.0; 5.5	2.2 – 8.2
	T _{max,ss} (h)	1.0*	–	–
	AUC _{0-24h,ss} (mg·h/L)	29.36 (12.47)	24.3; 34.4	16.2-76.1
	V _{ss} (L/kg)	1.81 (0.47)	1.6; 2.0	1.0 – 2.8
	Cl _{tot,ss} (L/h)	13.38 (4.79)	11.4; 15.3	3.0 – 22.2

CI, confidence interval; C_{\max} , maximal plasma concentration; AUC_{0-24h} , area under concentration time curve from time 0 to 24 hours; V_{ss} , volume of distribution at steady state; Cl_{tot} , total clearance
^a median; * $p < 0.01$ vs. PO

Table 3.

Steady-state concentration of moxifloxacin in inflamed DFI tissue and tissue/plasma ratio 3 hours following PO (n=28) or IV(n=25) administration of 400 mg moxifloxacin.

	PO (n=28)		IV (n=25)	
	Mean (SD)	Range	Mean (SD)	Range
DFI-tissue concentration ($\mu\text{g/g}$)	1.79 (0.82)	0.53 – 3.5	2.2 (1.54)	0.56 – 6.4
DFI tissue/plasma ratio	1.01 (0.57)	0.36 – 2.55	1.09 (0.69)	0.26 – 2.84

Table 4.

Predictive PK/PD parameters of moxifloxacin following once daily PO or IV administration of 400 mg for 4 to 8 days in 53 patients with DFI

PK/PD Parameters	$MIC_{90} = 0.25 \text{ mg/L}^{6,9,10}$		$MIC_{90} = 0.06 \text{ mg/L}^6$	
	PO	IV	PO	IV
C_{\max} / MIC_{90}	10.8 (3.8)	19.1 (7.5)	44.8 (15.7)	79.5 (31.2)
AUC_{0-24} / MIC_{90}	108.4 (43.4)	117.4 (49.9)	451.5 (180.9)	489.3 (207.8)

Acknowledgements

The authors express their thanks for the excellent technical assistance provided by Katrin Kroesche and Andrea Bruss. We thank Klaus A. Schmidt, Aachen, for his assistance in the preparation of the manuscript.

Results of an interim analysis of this study were presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France, April 2006; abstract P1516. [<http://www.blackwellpublishing.com/eccmid16/abstract.asp?id=50311>]

379 **Funding**

380 This study was supported in part by an unrestricted grant by Bayer Vital GmbH, Leverkusen,
381 Germany.

382

383 **Transparency declarations**

384 *Potential conflict of interest.*

385 J.M.P. has received speaking fee from Bayer Vital GmbH

386 M.S. no conflict

387 S.S. no conflict

388 V.C. has received research support from Bayer Vital GmbH

389 A.G. has received research support from Bayer Vital GmbH

390 R.L. has received speaking fee from Bayer Vital GmbH

391 R.G.M.has received research grants from Bayer Vital GmbH

392 C.L. no conflict

393 P.K. has received speaking fee from Bayer Vital GmbH

394 B.R. has received research grants from Bayer Vital GmbH

395 H.K. has received speaking fee from Bayer Vital GmbH

396 W.S. no conflict

397 E.K. has received research grants from Bayer Vital GmbH

398 B.D. has served as a consultant and received research grants from Bayer Vital GmbH

399

400

401

402

403

404

References

1. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS (2004) Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885-910
[\[http://www.journals.uchicago.edu/doi/full/10.1086/424846\]](http://www.journals.uchicago.edu/doi/full/10.1086/424846)
2. Lipsky BA, Giordano P, Choudhri S, Song J (2007) Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin–tazobactam/amoxicillin–clavulanate. J Antimicrob Chemother 60:370-376
[\[http://jac.oxfordjournals.org/cgi/content/abstract/60/2/370?etoc\]](http://jac.oxfordjournals.org/cgi/content/abstract/60/2/370?etoc)
3. Stengel D, Graninger W (2005) Antimicrobial treatment of diabetic foot infections. Effects of primary and secondary prevention measures on amputation rates. Chemotherapie Journal 14:191-197
[\[http://www.wissenschaftliche-verlagsgesellschaft.de/CTJ/CTJ2005/CTJ-6-05/stengel-1.pdf\]](http://www.wissenschaftliche-verlagsgesellschaft.de/CTJ/CTJ2005/CTJ-6-05/stengel-1.pdf)
4. Oberdorfer K, Swoboda S, Hamann A, Baertsch U, Kusterer K, Born B, Hoppe-Tichy T, Geiss HK, von Baum H (2004) Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 54:836-839
[\[http://jac.oxfordjournals.org/cgi/content/full/54/4/836\]](http://jac.oxfordjournals.org/cgi/content/full/54/4/836)
5. Majcher-Peszynska J, Haase G, Saß M, Mundkowski R, Pietsch A, Klammt S, Schareck W, Drewelow B (2008) Pharmacokinetics and penetration of linezolid

into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 64:1093–1100

<http://www.springerlink.com/content/703t7j5qr1w41165/>

6. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Nakeeb A, Cambria RA, Towne JB (2004) *In vitro* activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 48:1012-1016
[\[http://aac.asm.org/cgi/content/full/48/3/1012?view=long&pmid=14982797\]](http://aac.asm.org/cgi/content/full/48/3/1012?view=long&pmid=14982797)

7. Joukhadar C, Stass H, Müller-Zellenberg U, Lackner E, Kovar F, Minar E, Müller M (2003) Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 47:3099-3103
[\[http://aac.asm.org/cgi/content/full/47/10/3099?view=long&pmid=14506015\]](http://aac.asm.org/cgi/content/full/47/10/3099?view=long&pmid=14506015)

8. Wacke R, Förster S, Adam U, Mundkowsky RG, Klar E, Hopt UT, Drewelow B (2006) Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 58:994-999
[\[http://jac.oxfordjournals.org/cgi/content/full/58/5/994\]](http://jac.oxfordjournals.org/cgi/content/full/58/5/994)

9. Citron DM, Goldstein EJC, Merriam CV, Lipsky BA, Abramson MA (2007) Bacteriology of moderate-to-severe diabetic foot infections and *in vitro* activity of antimicrobial agents. J Clin Microbiol 45:2819-2828
[\[http://jcm.asm.org/cgi/content/full/45/9/2819?view=long&pmid=17609322\]](http://jcm.asm.org/cgi/content/full/45/9/2819?view=long&pmid=17609322)

10. Edmiston CE, Krepel CJ, Kehl KS, Seabrook GR, Somberg LB, Almassi GH, Smith TL, Loehrl TA, Brown KR, Lewis BD, Towne JB (2005) Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. *J Antimicrob Chemother* 56:872-878
[\[http://jac.oxfordjournals.org/cgi/content/full/56/5/872\]](http://jac.oxfordjournals.org/cgi/content/full/56/5/872)
11. Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, Bogner JR; The STIC Study Group (2009) Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections. *Infection* 37(5):407-417
<http://www.springerlink.com/content/c622602821776232/>
12. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP (2008) In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. *Antimicrob Agents Chemother* 52(11):3941-3946
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2573116/pdf/0589-08.pdf>
13. Stass H, Kubitza D (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. *J Antimicrob Chemother* 43:83-90
http://jac.oxfordjournals.org/cgi/reprint/43/suppl_2/83
14. Stass H, Dalhoff A (2005) The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. *Infection* 33:29-35
<http://www.springerlink.com/content/j651rt2833463465/>

15. Burkhard O, Welte T (2009) 10 years' experience with the pneumococcal quinolone
moxifloxacin. *Expert Rev Anti Infect Ther* 7(6):645-668
http://www.expert-reviews.com/doi/abs/10.1586/eri.09.46?url_ver=Z39.88-2003&rft_id=ori:rid:crossref.org&rft_dat=cr_pub%3dncbi.nlm.nih.gov
16. Gyssens IC, Dryden M, Kujath P, Nathwani D, Schaper N, Arvis P, Reimnitz P, Alder J, Hampel B. Efficacy of IV/oral moxifloxacin in the treatment of complicated skin and skin-structure infections: results of the RELIEF study. 19th European Congress of Clinical Microbiology and Infectious Diseases; Helsinki, Finland, 16 - 19 May 2009. P1785
<http://www.blackwellpublishing.com/eccmid19/abstract.asp?id=75391>
17. Wirtz M, Kleeff J, Swoboda S, Halaceli I, Geiss HK, Hoppe-Tichy T, Büchler MW, Friess H (2004) Moxifloxacin penetration into human gastrointestinal tissues. *J Antimicrob Chemother* 53(5):875-877
<http://jac.oxfordjournals.org/cgi/reprint/53/5/875>
18. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R (1999) Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. *J Antimicrob Chemother* 44(6):835-838
<http://jac.oxfordjournals.org/cgi/reprint/44/6/835>
19. Schaper N, Dryden M, Kujath P, Nathwani D, Arvis P, Reimnitz P, Alder J, Hampel B, Gyssens IC (2010) Efficacy of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanate in the treatment of diabetic foot infections: results of the RELIEF study. 20th European Congress of Clinical Microbiology and Infectious Diseases; Vienna, Austria, 9–13 April 2010. P1550
<http://www3.interscience.wiley.com/cgi-bin/fulltext/123359225/PDFSTART>

- 514 20. Bergogne-Berezin E (2002) Clinical role of protein binding of quinolones.
515 Clin Pharmacokinet 41(10):741-750
516 <http://www.ingentaconnect.com/content/adis/cpk/2002/00000041/00000010/art00004>
- 517 21. Pascual A, García I, Ballesta S, Perea EJ (1999) Uptake and intracellular activity of
518 moxifloxacin in human neutrophils and tissue-cultured epithelial cells.
519 Antimicrob Agents Chemother 43(1):12-15
520 <http://aac.asm.org/cgi/reprint/43/1/12>
521